Journal
EUROPEAN THYROID JOURNAL
Volume 2, Issue 2, Pages 76-82Publisher
KARGER
DOI: 10.1159/000351007
Keywords
Thyrotropin-secreting pituitary adenoma; Central hyperthyroidism; Thyrotropin; Resistance to thyroid hormones; Transsphenoidal surgery; Somatostatin analogs
Categories
Funding
- Wellcome Trust [095564] Funding Source: Medline
Ask authors/readers for more resources
Hyperthyroidism is mainly due to autoimmune thyroid disorders or toxic goiter, and very rarely to the presence of thyrotropin (TSH)-secreting pituitary adenomas (TSHomas). These tumors are characterized by high levels of circulating free thyroid hormones (FT4 and FT3) in the presence of non-suppressed serum TSH concentrations. Failure to correctly diagnose TSHomas may result in inappropriate thyroid ablation, which results in a significant increase of pituitary tumor mass. The diagnosis is mainly achieved by measuring TSH after T3 suppression and TRH stimulation tests. These dynamic tests, together with pituitary imaging and genetic testing are useful in distinguishing TSHomas from the syndromes of resistance to thyroid hormone action. The treatment of choice is surgery. In cases of surgical failure, somatostatin analogs have been found to be effective in normalizing TSH secretion in more than 90% of patients. Copyright (C) 2013 European Thyroid Association Published by S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available